FDA clears Olympus' narrow band imaging for bladder cancer biopsy
The FDA has granted 510(k) clearance to Olympus' Narrow Band Imaging technology designed for improved visualization of tumor boundaries in non-muscle-invasive bladder cancer.
The FDA found that the Olympus technology visualized NMIBS lesions in 17 percent more patient when compared with white light, 24 percent additional tumor and 28 percent additional carcinoma in situ.
The new technology can be used in both the office and operating room.
More articles on FDA clearances:
FDA clears Third Eye Panoramic device for colonoscopy
5 GI/endoscopy devices receive FDA 510(k) clearance in September
3 GI/endoscopy devices receive FDA 510(k) clearance in October
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- Republicans pull AHCA: 7 key notes
- The out-of-network co-pay conundrum – To waive or not to waive ... And how?
- Mobile apps equally effective as in-person visit following ambulatory surgery: 4 things to know
- Ambulatory services market to increase at 6% CAGR through 2024: 5 notes
- Dr. Cheryl Pegus: 5 strategies to becoming a physician leader